Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 14, 2015 06:27 ET | Source: Genmab A/S

Genmab indgår kommerciel licensaftale med Novo Nordisk om DuoBody teknologien

Selskabsmeddelelse Novo Nordisk tildelt to kommercielle licenser til DuoBody® teknologien Genmab modtager upfrontbetaling på USD 2 mio. København, Danmark; 14. august 2015 – Genmab A/S...
August 11, 2015 11:07 ET | Source: Genmab A/S

Genmab offentliggør resultat for første halvår 2015

11. august 2015: København, Danmark; Delårsrapport for første halvår 2015 Bemærk venligst at dette er et uddrag af delårsrapporten, og at den samlede delårsrapport for første halvår 2015 kun...
August 11, 2015 11:07 ET | Source: Genmab A/S

Genmab Announces Financial Results for the First Half of 2015

August 11, 2015; Copenhagen, Denmark; Interim Report First Half 2015 Rolling submission of BLA to U.S. FDA for daratumumab in double refractory multiple myeloma completed by Janssen,...
July 22, 2015 08:20 ET | Source: Genmab A/S

Genmab meddeler, at der er indsendt en supplerende registreringsansøgning til FDA for ofatumumab som vedligeholdelsesbehandling af recidiverende CLL

Selskabsmeddelelse Supplerende registreringsansøgning indsendt af Novartis til FDA i USA for ofatumumab som vedligeholdelsesbehandling af recidiverende CLL Ansøgningen er baseret på data...
July 22, 2015 08:20 ET | Source: Genmab A/S

Genmab Announces Submission of Supplemental Biologics License Application to FDA for Ofatumumab as Maintenance Therapy for Relapsed CLL

Company Announcement sBLA submitted to US FDA for ofatumumab as maintenance therapy in relapsed CLL by Novartis Submission based on data from interim results of Phase III PROLONG...
July 10, 2015 11:50 ET | Source: Genmab A/S

Storaktionærmeddelelse

Selskabsmeddelelse Storaktionærmeddelelse for Genmab A/S København, Danmark, 10. juli 2015 – Genmab A/S (OMX: GEN) skal under henvisning til Værdipapirhandelslovens § 29 meddele, at ATP har...
July 10, 2015 11:50 ET | Source: Genmab A/S

Major Shareholder Announcement

Company Announcement Major shareholder announcement for Genmab A/S Copenhagen, Denmark; July 10, 2015 – Genmab A/S (OMX: GEN) announces under reference to Section 29 of the Danish Securities...
July 09, 2015 13:47 ET | Source: Genmab A/S

Genmab offentliggør færdiggørelsen af en løbende registreringsansøgning (Rolling Biologics License Application) for daratumumab i myelomatose og opnåelsen af en milepælsbetaling på USD 15 mio.

Selskabsmeddelelse Janssen Biotech, Inc. færdiggør indleveringen af den løbende BLA-ansøgning til FDA i USA for daratumumab i myelomatose Færdiggørelsen af indleveringen udløser en...
July 09, 2015 13:47 ET | Source: Genmab A/S

Genmab Announces Completion of Rolling Submission of Biologics License Application for Daratumumab in Multiple Myeloma and Achievement of a USD 15 Million Milestone

Company Announcement Submission of rolling BLA to US FDA for daratumumab in multiple myeloma completed by Janssen Biotech, Inc. Completion of submission triggers USD 15 million milestone...
July 07, 2015 07:29 ET | Source: Genmab A/S

Genmab Announces European Regulatory Submission for Ofatumumab as Maintenance Therapy for Relapsed CLL

Company Announcement Application to broaden label for ofatumumab as maintenance therapy in relapsed CLL submitted to EMA by Novartis Submission based on data from interim results of Phase...